aTyr Pharma Presents at American Society of Human Genetics 2018 Meeting
October 17 2018 - 08:00AM
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged
in the discovery and development of innovative medicines based on
novel immunological pathways, today announced a presentation at the
American Society of Human Genetics 2018 Meeting in San Diego,
California from October 16 - 20, 2018.
Presentation: Wednesday, October 17, 2018 from 6:30 to
6:45 pm (PDT)
Title: “Bi-allelic mutations in Phe-tRNA
synthetase identified from four families are associated with a
multi-system disease and support ex-translational function”
Presenter: Zhiwen Xu, Ph.D., aTyr Pharma,
Inc.
Conclusions:
- Mutations have been increasingly identified in aminoacyl tRNA
synthetases which are associated with various serious disease
states.
- This presentation highlights a new class of mutations in
Phe-tRNA synthetase (FARS) which do not affect protein synthesis,
but are associated with multi-system disease with common features
of hypotonia and interstitial lung disease with cholesterol
pneumonitis.
- These results support a disease mechanism independent of
protein translation and suggest that this FARS activity is
essential for normal function in multiple organs, particularly lung
and brain.
About aTyraTyr is a
biotherapeutics company engaged in the discovery and development of
innovative medicines based on novel immunological pathways.
aTyr’s research and development efforts are concentrated on a
newly discovered area of biology, the extracellular functionality
of tRNA synthetases. aTyr has built a global intellectual property
estate directed to a potential pipeline of protein compositions
derived from 20 tRNA synthetase genes. aTyr is focused on the
therapeutic translation of the Resokine pathway, comprised of
extracellular proteins derived from the histidyl tRNA synthetase
gene family. ATYR1923 is a clinical-stage product candidate which
binds to the neuropilin-2 receptor and is designed to down-regulate
immune engagement in interstitial lung diseases and other
immune-mediated diseases. For more information, please visit
http://www.atyrpharma.com.
Forward-Looking StatementsThis
press release contains forward-looking statements within the
meaning of the Private Litigation Reform Act. Forward-looking
statements are usually identified by the use of words such as
“anticipates,” “believes,” “estimates,” “expects,” “intends,”
“may,” “plans,” “projects,” “seeks,” “should,” “will,” and
variations of such words or similar expressions. We intend
these forward-looking statements to be covered by such safe harbor
provisions for forward-looking statements and are making this
statement for purposes of complying with those safe harbor
provisions. These forward-looking statements, including
statements regarding the potential therapeutic benefits and
applications of our product candidates; our ability to successfully
advance our product candidates, undertake certain development
activities (such as the initiation of clinical trials, clinical
trial enrollment, the conduct of clinical trials and the
announcement of top-line results) and accomplish certain
development goals, and the timing of such events; and the scope and
strength of our intellectual property portfolio. These
forward-looking statements also reflect our current views about our
plans, intentions, expectations, strategies and prospects, which
are based on the information currently available to us and on
assumptions we have made. Although we believe that our plans,
intentions, expectations, strategies and prospects, as reflected in
or suggested by these forward-looking statements, are reasonable,
we can give no assurance that the plans, intentions, expectations
or strategies will be attained or achieved. Furthermore,
actual results may differ materially from those described in these
forward-looking statements and will be affected by a variety of
risks and factors that are beyond our control including, without
limitation, risks associated with the discovery, development and
regulation of our product candidates, the risk that we may cease or
delay preclinical or clinical development activities for any of our
existing or future product candidates for a variety of reasons
(including difficulties or delays in patient enrollment in planned
clinical trials), and the risk that we may not be able to raise the
additional funding required for our business and product
development plans, as well as those risks set forth in our most
recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q
and in our other SEC filings. Except as required by law, we
assume no obligation to update publicly any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Contact: |
Jason Spark |
Managing Director, Canale Communications Inc. |
jason@canalecomm.com |
619-849-6005 |
aTyr Pharma (NASDAQ:LIFE)
Historical Stock Chart
From Feb 2024 to Mar 2024
aTyr Pharma (NASDAQ:LIFE)
Historical Stock Chart
From Mar 2023 to Mar 2024